Swiss Hepatitis C Cohort Study
Information for participants

Dear Madam / Sir:

The hepatitis C virus may cause a persisting inflammation of the liver. This disease requires a specialized management, and regular controls over the following years. We invite you to participate into a cohort study (i.e. a registry) that could lead us to better understand of the spread of this disease in Switzerland, its modalities of transmission, its mechanisms and its natural course or upon antiviral treatment. These data may help us to fight this disease in a more effective way.

Your consent is voluntary and may be revoked at any time. Moreover, your decision will not affect your medical treatment. Please take as much time as you need to communicate us your decision.

To help you make your decision, the main information is summarised in this leaflet.

Aims of the study
The primary aim of this study is to follow on a regular basis and with standardised tools a great number of patients who are representative of the whole population of patients infected with the hepatitis C virus in Switzerland, in order to better understand and treat this disease. At the same time we will collect and freeze blood samples to perform further analysis.

General information regarding this clinical study
Every participant to the Swiss hepatitis C cohort study and all study physicians are informed of its progress. This is a study conducted in several Swiss institutions simultaneously (multi-center study) and will bring together about 7,000 patients in our country.

The participation in the study entails:
1) The collection – once a year – of some data concerning your health status and medical history;
2) The collection – once a year – of approximately 20 ml of blood.

The blood samples will be stored in a biobank for further analysis, which may help improve our knowledge about the disease and possible treatments. If, during the course of the normal management of your disease, there is a medical indication to perform a liver biopsy, we reserve the right to store some fragments of your liver tissue for further analyses.
Course of the study for the participants

Data collection occurs once a year during a routine consultation at the agreed place and does not require additional medical visits. In addition, during these visits, an additional blood sample is taken (approximately 20 ml of blood).

When the participant receives an antiviral therapy, additional time points are foreseen at baseline pre-treatment, week 2, week 4, week 12 or week 24 if applicable, otherwise at end of treatment and 12 weeks after the end of treatment. At the time of these treatment-related visits, an additional blood sample is taken for the study (approximately 6 ml of blood).

Obligations of participants

As a participant into the study you are expected:

- To attend the routine annual visits. Unless otherwise stated by you, we reserve the right to seek to contact you in case of absence to one of these visits, in order to have news about your health. This research may include various means such as contacting the municipality of your last known address
- To tell your doctor-investigator of the evolution of the disease and report any new symptoms, any new problem and any change in your status
- To inform your doctor-investigator of any treatment or concomitant therapy, prescribed by another physician; to also inform about all medicines you may be taking, even in case of, for example, medicines you bought yourself and for which you do not need a prescription, including herbal teas, natural products, or alternative medicine drugs (homeopathy and so on).

It is possible that your physician-investigator withdraws you from the study for a valid reason, for example in case the study is terminated.

Benefits for the participants

By participating in this clinical trial, you should not expect a direct benefit. The results of research projects are generally published and may help to improve the treatment of future patients.

Risks and constraints for the participants

To participate in this cohort study does not present any specific risk. The only drawback is an additional blood test once a year.

Discoveries made during the study

In many cases, the results of research are not relevant for the individual patient. However, if a study does yield results which are directly relevant to your health, and preventive or therapeutic measures would be possible, you have a right to be informed of this. If you wish to exercise this right to receive information, you must indicate this on the consent form.

Voluntary participation

Your participation in this study is voluntary. Refraining from taking part in this study will have no impact on your future medical care. The same applies to the revocation of your initial consent. Therefore, you can quit the study at any time. You are not required to justify your
revocation of consent or the possible withdrawal. However, unless otherwise stated by you, hitherto collected data and samples will continue to be used.

Your consent
If you give your consent, your biological material, genetic data and health-related data can be made accessible to biomedical research. This means that your biological material and health-related data can be passed on to researchers or to another institution for research purposes, under the conditions specified below. As long as it is not revoked, your consent applies to all future projects approved by ethical committees. Accordingly, you will not be informed each time your biological material and health-related data are used in research projects or passed on to another institution.

Health-related data
The term “health-related data” covers all the data in the patient record – e.g. data on possible risk factors and the results of clinical, imaging or laboratory (chemical) tests and genetic analyses obtained by the physician investigating your condition. It also covers data concerning the course of disease and the response to treatment.

Protection of biological material and of health-related data
The institution undertakes to store your biological material securely. Access to your biological material and health-related data is clearly regulated. Only authorised and clearly defined persons at the institution have access to the uncoded personal data and to the coding key. It may be that some samples and information about your health are anonymized irreversibly.

Coding and anonymisation
Coding means that all the details that could identify you (e.g. name, date of birth, etc.) are replaced by a code, so that it is not possible for data to be linked to your person by anyone who does not know the code. Within the HUG, the data can also be accessed in uncoded form by authorised and clearly defined persons. The coding key always remains in the HUG. Some encoded data may be anonymised by permanently deleting the code or decoding key. After this irreversible anonymisation, nobody can know that these data and this material are yours, and this is the reason why any request for destruction of anonymised samples can not be taken into consideration.

Use of biological material and health-related data
All research projects involving the use of your biological material and/or health-related data have to be approved in advance by the responsible ethics committee. The HUG can only pass on the biological material and health-related data to researchers in coded form. The researchers may work at institutions such as hospitals, universities or industrial companies either in Switzerland or abroad. However, the country in question must have legal requirements for data protection which are at least equivalent to those applicable in Switzerland.
Costs and compensations for the participants

Data collection occurs once a year during a routine consultation as part of the normal management of your disease. Thus, your participation to the study does not generate any extra costs for you or for your health insurance. No compensation is provided for the participation in this study.

Participants to the study cannot claim any rights on the commercial exploitation of biological material or health-related data

The results of research projects may also contribute to the development of commercial products, such as new drugs. But research involving biological material and health-related data is just a small component in this process. This means that you have no claims with regard to commercial exploitation or patents associated with your biological material and health-related data.

Legal aspects

This study is conducted in accordance with the Swiss law and internationally recognized guidelines. It has been approved by the Ethics Committee on Research on humans at the HUG. This study is funded by the Swiss National Science Foundation (NSF), the Swiss Hepatitis C Cohort Study Foundation and other profit and nonprofit parties.

Contact person(s)

You can always contact us to obtain information on your personal data. If you have questions or want to know more about it, you can at any time refer to the following contact person:

Prof. Francesco Negro
Principal Investigator of the study
Services de Gastroentérologie et d’hépatologie, Hôpitaux Universitaires de Genève, rue Gabrielle-Perret-Gentil 4, 1211 Genève,
Email: Francesco.Negro@hcuge.ch  Tél. 022-3729355

In case of an emergency, please contact the specialist on call (7/7, 24/24) at the Service de Gastroentérologie et d’hépatologie.
Phone : 079 55 34520 (day) ou 074 055 02 87 (night)
Written declaration of consent to participate to this study

- Please read carefully this form

Number of the study: 00-28
Name of the study: Swiss Hepatitis C Cohort Study
Promoter: Prof. Francesco Negro
Hôpitaux Universitaires de Genève
Département de Médecine Interne
Division de Gastroentérologie et d’Hépatologie
Principal Investigator: Prof. Francesco Negro
Place where the study is carried out: Hôpitaux Universitaires de Genève (HUG)
Genève

Other clinicians:

Participant
(surname / first name):
Date of birth: □ female □ male

- I declare that I have been informed by the undersigned physician, orally and in writing, about the goals and course of the Swiss Hepatitis C Cohort Study;
- I declare having read and understood the written information to patients that was given to me, dated 15/04/2015 and that I have received a copy of my written consent;
- I received satisfactory answers to the questions I posed in connection with my participation in the study;
- I take part in this study voluntarily. I can, at any time and without having to justify myself, revoke my consent to participate in the study, without this having an adverse impact on the rest of my medical care;
- I had enough time to make my decision;
- I accept the content of the information sheet given to me on the above study;
- I know that my personal data will be transmitted only in coded or anonymised form to external institutions for research purposes. I agree that the competent specialists of the representatives of the study, the authorities and the Cantonal Ethics Commission may consult my raw data (not encoded and non-anonymous) to conduct examinations and inspections, provided, however, that their confidentiality is strictly guaranteed;
- I have been sufficiently informed of the reuse of biological material and health-related data for biomedical research. I agree that (i) the biological material that was taken from me as part of the study (blood) or in case of procedures performed for diagnostic purposes or in view of a treatment (liver biopsy), and (ii) the data about my illness be reused as part of biomedical research;
- I know that, as a donor, I have the right to be informed of results which are directly relevant to my health. I am aware that I will only be informed if I have indicated – by checking the box on this consent forms (see below) – that I wish to exercise my right to receive information.
☐ I wish to be informed about the results regarding directly my health (as long as it is possible to contact me and to communicate to me such information).

<table>
<thead>
<tr>
<th>Place / date</th>
<th>Signature of the participant or of his/her legal representative</th>
</tr>
</thead>
</table>

203

**Certification of the doctor-investigator**: I am herewith certifying that I have explained to the participant the nature, size and scope of the study. I declare to fulfil all the obligations to this study in accordance with the law. If at any given time during the study I came to know new elements that may influence the consent of the participant to take part in the study, I agree to inform him/her immediately.

<table>
<thead>
<tr>
<th>Place / date</th>
<th>Signature of the investigator</th>
</tr>
</thead>
</table>

204

205

206

207

208

209